ABBVIE
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 136
- Registration Number
- NCT02723084
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 197
- Registration Number
- NCT02720523
- Locations
- 🇯🇵
Nagoya University Hospital /ID# 148005, Nagoya-shi, Aichi, Japan
🇯🇵Hamanomachi Hospital /ID# 147991, Fukuoka-shi, Fukuoka, Japan
🇯🇵Sapporo City General Hospital /ID# 147968, Sapporo, Japan
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT02719171
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
- Conditions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 273
- Registration Number
- NCT02713295
- Locations
- 🇬🇷
PP of Ekaterini Galaterou /ID# 149713, Athens, AGIA Paraskeui, Greece
🇬🇷PP of Antonios Seretis /ID# 149714, Athens, Chalandri, Greece
🇬🇷PP of Maria Loukatou /ID# 149706, Athens, Glyfada, Greece
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT02709889
- Locations
- 🇺🇸
Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States
🇺🇸Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States
🇺🇸Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 295
- Registration Number
- NCT02707952
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1002
- Registration Number
- NCT02706873
- Locations
- 🇯🇵
Hokkaido University Hospital /ID# 148262, Sapporo, Japan
🇺🇸TriWest Research Associates- La Mesa /ID# 143738, La Mesa, California, United States
🇺🇸Desert Medical Advances /ID# 143730, Palm Desert, California, United States
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 648
- Registration Number
- NCT02706951
- Locations
- 🇺🇸
W. Broward Rheum Assoc Inc. /ID# 146010, Tamarac, Florida, United States
🇺🇸Sarasota Arthritis Center /ID# 146011, Sarasota, Florida, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 147175, Tucson, Arizona, United States
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 499
- Registration Number
- NCT02706847
- Locations
- 🇺🇸
AZ Arthritis and Rheum Assoc /ID# 148593, Mesa, Arizona, United States
🇺🇸NEA Baptist Clinic /ID# 149280, Jonesboro, Arkansas, United States
🇺🇸New England Research Associates, LLC /ID# 142763, Bridgeport, Connecticut, United States
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 684
- Registration Number
- NCT02694523